免疫性血小板减少症与妊娠:暴露/非暴露队列研究
该前瞻性多中心观察性队列研究纳入180例妊娠和168例非妊娠免疫性血小板减少症(ITP)女性,按脾切除史、ITP状态和病程匹配131对,随访15个月。妊娠组与非妊娠组首次ITP恶化风险无显著差异,但妊娠组严重血小板减少复发和治療调整风险更高;新生儿ITP发生率为14%,与既往新生儿ITP史和分娩前3个月内母体血小板计数<50×10⁹/L相关。
要点
- 妊娠不增加ITP女性严重出血风险,但严重血小板减少复发和治疗调整风险升高。
- 新生儿ITP发生率为14%(19例新生儿血小板<50×10⁹/L)。
- 新生儿ITP与既往新生儿ITP史及分娩前3个月内母体血小板<50×10⁹/L相关。
核心结论
- ITP女性妊娠期间不增加严重出血风险。
- 新生儿ITP与既往新生儿ITP史及妊娠期间母体ITP严重程度相关。
- 这些结果有助于为ITP女性提供咨询。
研究设计与样本
- 前瞻性、多中心、观察性队列研究,纳入180例妊娠和168例非妊娠ITP女性。
- 按脾切除史、ITP状态(无反应、反应、完全反应)和病程匹配131对妊娠与非妊娠ITP女性。
- 随访15个月。
主要发现
- 首次ITP恶化(复合终点包括出血事件和/或严重血小板减少<30×10⁹/L和/或ITP治疗调整)在妊娠组与非妊娠组无显著差异:妊娠组53.4/100人年(95%CI 40.8-69.9) vs 非妊娠组37.1/100人年(95%CI 27.5-50.0),HR 1.35(95%CI 0.89-2.03),P=0.16。
- 妊娠组严重血小板减少复发风险高于非妊娠组:HR 2.71(95%CI 1.41-5.23),P=0.003。
- 妊娠组治疗调整风险高于非妊娠组:HR 2.01(95%CI 1.14-3.57),P=0.017。
- 严重出血事件复发在两组间无差异(P=0.4)。
- 19例(14%)新生儿发生新生儿ITP(血小板<50×10⁹/L)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The risk of immune thrombocytopenia (ITP) worsening during pregnancy and neonatal ITP (NITP) have never been prospectively studied. We included 180 pregnant and 168 nonpregnant women with ITP in a prospective, multicenter, observational cohort study. A total of 131 pregnant women with ITP were matched to 131 nonpregnant women with ITP by history of splenectomy, ITP status (no response, response, complete response), and duration. Groups were followed for 15 months. The primary outcome was the first occurrence of ITP worsening defined by a composite end point including bleeding events and/or severe thrombocytopenia (<30 × 109/L) and/or ITP treatment modification. We also studied the recurrence of ITP worsening and the incidence of NITP and risk factors. The first occurrence of ITP worsening did not differ between pregnant and nonpregnant women with ITP (53.4 per 100 person-years [95% confidence interval {CI}, 40.8-69.9] vs 37.1 [95% CI, 27.5-50.0]; hazard ratio {HR}, 1.35 [95% CI, 0.89-2.03], P = .16). Pregnant women with ITP were more likely to have recurrence of severe thrombocytopenia and treatment modification (HR, 2.71 [95% CI, 1.41-5.23], P = .003; HR, 2.01 [95% CI, 1.14-3.57], P = .017, respectively). However, recurrence of severe bleeding events was not different between groups (P = .4). Nineteen (14%) neonates showed NITP <50 × 109/L. By multivariable analysis, NITP was associated with a previous offspring with NITP and maternal platelet count <50 × 109/L within 3 months before delivery (adjusted odds ratio, 5.55 [95% CI, 1.72-17.89], P = .004 and 4.07 [95% CI, 1.41-11.73], P = .009). To conclude, women with ITP do not increase their risk of severe bleeding during pregnancy. NITP is associated with NITP history and the severity of maternal ITP during pregnancy. These results will be useful for counseling women with ITP.
引用
- Guillet S, Loustau V, Boutin E, et al. Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study. Blood. 2023. PMID: 36054922. doi:10.1182/blood.2022017277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。